Canada’s Drug Agency, with support from our health system partners including ICES and Health Data Research Network Canada (HDRN), has published a new roadmap that will help those who manage patient and disease registries in Canada navigate the process of linking data records to help answer relevant…
Canada’s Drug Agency is pleased to announce the successful applicants from our 2024 Request for Proposals (RFP) to support the enhancement of rare disease registries in Canada. The awarded rare disease registries span diverse disease areas and will undertake varied improvement initiatives, all with…
Drug sponsors can now request a flexible service through our Scientific Advice program that can include a shorter time frame.
For Scientific Advice after pivotal trials designs are finalized, the program now offers more timely advice on anticipated key uncertainties or evidence gaps based on the…
Canada’s Drug Agency has released new guidance around aging in place. This guidance is intended to help health systems address Canada’s demographic transition toward an increasingly diverse aging population with an increased need for care and support during the later stages of life.
As health…
Today’s the day: we are officially Canada’s Drug Agency.
We are expanding on our existing mandate and functions — which span drugs, medical devices, and clinical interventions — and including developing new programs focused on appropriate use, data and analytics, and system coordination and…
Canada’s Drug Agency has published a national inventory of rare disease registries (RDRs) that includes both registries in Canada and international registries with participants who live in Canada.
The inventory is designed to serve as a centralized, thorough repository of registries that collect…
Canada’s Drug Agency is pleased to announce the recipients of our 2024 Recognition Awards. These awards honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada’s reputation for excellence in…
A new Environmental Scan from Canada’s Drug Agency examines Canadian data related to alternate level of care (ALC) and the effectiveness of strategies health systems use to reduce ALC times.
ALC is a designation that refers to people who occupy a hospital bed, but who don’t require the intensity of…
Canada’s Drug Agency has published a summary report from its time-limited Industry Task Force. The report outlines key actions for the organization, and the broader health care community, that can enable the use of industry-sponsored real-world evidence (RWE) to help improve our understanding of…
Patients in Canada with advanced-stage lymphoma are 1 step closer to accessing the first drug to receive a time-limited reimbursement recommendation from Canada’s Drug Agency.
Epcoritamab (brand name Epkinly) is a subcutaneous bispecific antibody used to treat adults with relapsed or refractory…
Last week, the Government of Canada released the final report from the Canadian Drug Agency Transition Office’s (CDATO) Appropriate Use Advisory Committee on the appropriate use of medications.
These recommendations and the strong foundation established by the CDATO will support Canada’s Drug…
Canada’s Drug Agency is taking a new step to improve the timeliness of patient access to new drugs. The action supports our ambitious Target Zero campaign — an initiative that aims to achieve zero days between Health Canada’s regulatory approval of a drug and our reimbursement recommendation to…